SESSION 4:
Maximizing IP Value in Bioscience Investment
Developing intellectual property assets that provoke investor interest is critical to early-stage bioscience entrepreneurs. Every IP decision, especially decisions related to the company’s patents and the potential patents of others, can impact the value of the assets and any investment in the company.
The goal of this session is to highlight the important IP concepts, timelines, costs, and perils that confront the start-up and venture-backed company to maximize the first and next funding round.
SESSION 5:
Regulatory Planning for the U.S. & Global Market – Implications for Strategy and Financing
In regulated markets, FDA approval is needed to obtain a license to sell, and may define the positioning of your product. Obtaining regulatory approval is one of the most costly activities of a life sciences startup.
This session provides the specific insight into planning for U.S. and global regulations and clinical trials. What are the considerations and the challenges that startups might encounter?
SESSION 6:
The R&D – Marketing Interface
The goal of drug development is commercial and investor success. By expanding upon a strategic development tool based upon FDA Guidance called the target product profile (TPP), alignment of R&D, reimbursement, pricing, regulatory, label claim, IP, marketing, and sales strategies are aided. The TPP ensures product strategy and commercialization plan details do not disconnect. This tool is applicable to all life science verticals.
This session provides the format and walks the student how to prepare one for their firm.
SESSION 10:
The Business Plan and Pitch in the Fund-Raising Process
The business plan details your effective growth and market strategies, the soundness of your operational tactics, and understanding of funding needs and timing. Your investor pitch is the 10-20 slide hook to get investors interest in reading your business plan.
Experienced entrepreneurs and their investors openly recognize that within a year of operating, few companies resemble their original business plan.
However, these documents provide the starting point of a shared vision and evidence that the founding team can reach a consensus in the business and technology and resource planning process to meet critical milestones.
The session provides a framework for developing a pitch to investors/partners, and the essentials of a business plan.
SESSION 11:
Accelerating Creditability and Valuation by Leveraging Partners
The Business Model (which supports the business plan) contains all elements required by a firm to create, deliver, and capture value. In developing and validating the business model elements, the firm can leverage the resources and channels of partners across the value chain and share the value created and delivered with others.
This session will provide a working model to consider which elements of your business model may be best served with leveraging partners.
SESSION 12:
Group & Presentations
Utilizing the worksheet provided, students will discuss and identify the areas where partnerships could either accelerate, de-risk, or deepen domain relationships.
SESSION 16:
Early-Stage Funding Pitch
The objective of this session is to witness real-life feedback and understand the expectations of investors at the early-stage valuation point.
SESSION 17:
Group & Presentations
Utilizing the feedback given, students will discuss and identify areas of improvement in their pitches.
SESSION 18:
Working with the Media: Thoughts for Bio-Entrepreneurs
Presented by Moira A. Gunn, Host of National Public Radio Tech Nation
Register Now!
Sunday June 4 – Monday June 5, 2023
Boston Convention and Exhibition Center
(415 Summer St. Boston, MA 02210)
In the Seaport District of Boston, MA
Add this course to your
BIO International Registration
Register Now!
Sunday June 4 – Monday June 5, 2023
Boston Convention and Exhibition Center
(415 Summer St. Boston, MA 02210)
In the Seaport District of Boston, MA
Add this course to your
BIO International Registration